Unione Europea - italiano - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - agenti antitrombotici - xarelto, co-somministrato con acido acetilsalicilico (asa) da solo o con asa più clopidogrel o ticlopidina, è indicato per la prevenzione di eventi atherothrombotic in pazienti adulti dopo una sindrome coronarica acuta (acs) con elevata biomarcatori cardiaci. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevenzione del tromboembolismo venoso (tev) in pazienti adulti sottoposti a chirurgia sostitutiva elettiva dell'anca o del ginocchio. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - rivaroxabanum - compresse rivestite con film - rivaroxabanum 10 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 27.9 mg, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 3350, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 0.6 mg. - thromboseprophylaxe e trattamento di ictus e embolieprophylaxe, trattamento dell'embolia polmonare (le) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - rivaroxabanum - compresse rivestite con film - rivaroxabanum 15 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 25.4 mg, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 3350, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 0.6 mg. - thromboseprophylaxe e trattamento di ictus e embolieprophylaxe, trattamento dell'embolia polmonare (le) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - rivaroxabanum - compresse rivestite con film - rivaroxabanum 20 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 22.9 mg, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 3350, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 0.6 mg. - thromboseprophylaxe e trattamento di ictus e embolieprophylaxe, trattamento dell'embolia polmonare (le) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - rivaroxabanum - compresse rivestite con film - rivaroxabanum 2.5 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 36 mg, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 3350, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 0.6 mg. - in combinazione con acido acetilsalicilico per la prevenzione di gravi atherothrombotischer eventi nei pazienti con malattia coronarica o franca periferico arterioso gefässerkrankung e un elevato rischio di eventi ischemici - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenti antitrombotici - prevenzione del tromboembolismo venoso (tev) in pazienti adulti sottoposti a chirurgia sostitutiva elettiva dell'anca o del ginocchio. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 per haemodynamically instabile pe pazienti). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 e 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

vi.rel pharma s.r.l - rivaroxaban - rivaroxaban

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

zaklady farmaceutyczne polpharma sa - rivaroxaban - rivaroxaban

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

hcs bv - rivaroxaban - rivaroxaban

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - rivaroxabanum - granulato per sospensione orale - rivaroxabanum 1.0 mg, acidum citricum, hypromellosum, mannitolum, cellulosum microcristallinum et carmellosum natricum, e 211 1.8 mg, sucralosum, xanthani gummi, aromatica, maltodextrinum, propylenglycolum, acaciae gummi, ad granulatum corresp. suspensio reconstituta 1 ml corresp. natrium 0.5 mg. - behandlung und prophylaxe von venösen thromboembolien bei pädiatrischen patienten - synthetika